Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under ...

Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Failures at Novartis have prompted U.K. | Failures at Novartis have prompted the U.K. marketing watchdog to warn that “companies should be on high alert” when working with third parties to ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest ...

Swiss pharmaceutical giant Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities, as drugmakers brace for potential tariffs from the Trump administration.

Novartis Gene Therapies cancels Durham North Carolina jobs project, keeps previous hiring incentive, citing lower growth projections ...

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, which would save the company $1 billion over the next two years Global drugmaker Novartis will lay off 427 employees who ...

Novartis secured a $745 million partnership with radiopharmaceutical biotech Ratio Therapeutics to develop a cancer candidate, the companies announced Monday morning. Through the collaboration, ...

Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court ...

Drugmaker Novartis' second-quarter results were better than expected. Profit guidance for the remainder of the year was also raised. The pharma company, however, rattled the market with a decision ...